Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics (CYTK) had its price target raised by Mizuho from $84.00 to $100.00. They now have an "outperform" rating on the stock.
Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $74.00 to $75.00. They now have an "overweight" rating on the stock.
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes [Yahoo! Finance]
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo [Yahoo! Finance]